CLOs on the Move

Social Interest Solutions

www.oneeapp.org

 
Social Interest Solutions is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Oakland, CA. To find more information about Social Interest Solutions, please visit www.oneeapp.org
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.oneeapp.org
  • 1333 Broadway Ste 1020
    Oakland, CA USA 94612-1926
  • Phone: 510.834.1300

Executives

Name Title Contact Details

Similar Companies

National Stroke Association

National Stroke Association is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Awair

Our mission at Awair is to empower you with the knowledge, motivation, and confidence to be healthy and thrive in your environment.

Massachusetts Senior Care Association

Massachusetts Senior Care Association is a Columbus, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Masimo Corporation

Masimo Corporation is a global medical technology company that develops, manufactures and markets non-invasive patient monitoring products.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.